Session 8: Hemophilia
Tracks
Plenary Hall
| Saturday, December 19, 2026 |
| 12:55 PM - 2:00 PM |
Speaker
Dr. Flora Peyvandi
Director of the Department of Pathophysiology and Transplantation
Director of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
SHL vs EHL treatment in Hemophilia
12:55 PM - 1:15 PMBiography
Dr. Gerry Dolan
Consultant Haematologist and Hemophilia Centre Director
St Thomas’ Comprehensive Care Centre
Non-factor Replacement (Emicizumab/Fitusiran and other options)
1:15 PM - 1:35 PMBiography
Dr. Gerry Dolan is a consultant hematologist and hemophilia centre director at St Thomas’ Comprehensive Care Centre, London, UK, and former centre director at Nottingham University Hospitals, Nottingham, UK. He is former chairman of the UK Hemophilia Centre Directors and president of the British Society for Haemostasias & Thrombosis. He has been an active participant in collaborative European initiatives in hemophilia and has chaired initiatives such as the ADVANCE group and the European Hemophilia Therapy Standardization Board. His interests include novel agents in the treatment of hemophilia, gene therapy and clinical outcomes.
Dr. Flora Peyvandi
Director of the Department of Pathophysiology and Transplantation
Director of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
Gene Therapy
1:35 PM - 1:55 PMBiography
Session Chair
Shehab Fareed
Consultant Hematology
Hamad Medical Corporation - HMC
Ahmad Tarawah
President, Madinah Hereditary Blood Disorders Society
President, Middle East and North Africa Hematology League